These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 29131246)

  • 41. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
    Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
    Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers.
    Xiong SQ; Lin BL; Gao X; Tang H; Wu CY
    Int Immunopharmacol; 2007 May; 7(5):578-87. PubMed ID: 17386405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
    Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
    J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Detection of antigen-epitope-specific cytotoxic T lymphocytes in patients with hepatitis B virus infection by enzyme linked immunospot assay].
    Zhang HP; Yan HP; Zhang YH; Feng X; Zhao Y; Liao HY; Liu YM; Chen Y; Tan YF; Liu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):690-4. PubMed ID: 20021848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B.
    Ge J; Wang K; Meng QH; Qi ZX; Meng FL; Fan YC
    J Clin Immunol; 2010 Jan; 30(1):60-7. PubMed ID: 19756987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmed death 1 expressing CD8
    Khanam A; Tang LSY; Kottilil S
    Hepatology; 2022 Mar; 75(3):690-708. PubMed ID: 34689344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood.
    Colombatto P; Barbera C; Bortolotti F; Maina AM; Moriconi F; Cavallone D; Calvo P; Oliveri F; Bonino F; Brunetto MR
    J Med Virol; 2018 Jul; 90(7):1232-1239. PubMed ID: 29488227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies.
    Xiang Y; Chen P; Xia JR; Zhang LP
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns.
    Shrivastava S; TrehanPati N; Patra S; Kottilil S; Pande C; Trivedi SS; Sarin SK
    J Viral Hepat; 2013 Aug; 20(8):582-91. PubMed ID: 23808997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Correlation of qAnti-HBc with antiviral efficacy in children with chronic hepatitis B and exploration of its possible immune mechanism].
    Zhou YZ; Chang YN; He Y; Wang HM; Peng XR; Chen M; Peng ML; Hu P; Ren H; Xu HM
    Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):837-843. PubMed ID: 34638201
    [No Abstract]   [Full Text] [Related]  

  • 58. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
    PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.